Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Gilead Sciences (GILD) · oqro.io/stocks/GILD · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Have Gilead Sciences insiders bought shares recently?
No open-market purchase by an insider of Gilead Sciences was filed in the last 90 days. The latest on record was on Feb 6, 2015.
How often do Gilead Sciences insiders buy and sell shares?
Since 2006, Gilead Sciences insiders reported 8 open-market purchases and 2,865 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2015.
Who is selling Gilead Sciences stock?
In the last 90 days, 6 insiders of Gilead Sciences (GILD) reported 32 open-market sales worth $41.6M in total on SEC Form 4. The largest seller by value was Daniel Patrick O'day, with $29.5M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade GILD?
Yes. Members of Congress disclosed 4 trades in Gilead Sciences (GILD) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Sen. Alan Armstrong, Rep. Jared Moskowitz (FL23), Rep. Josh Gottheimer (NJ05).
When does Gilead Sciences report its next results?
Gilead Sciences's next results are expected on Feb 8, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+33.2% (+$41.44) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $124.99 on Nov 20, 2025 to $166.43 on Nov 20, 2026 (+33.2%). Disclosed in this range: 1 insider trade, 87 pre-arranged insider sales, 4 Congress trades, and 222 13F position changes for 4 quarters ending in it.
$100$120$140$180$166.43
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 92 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in Foster City, California.
Last 12 months
+30.0%
S&P 500 +8.0% over the same dates
Market value
$207B
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 21.3M shares sold short (1.7% of shares outstanding), +4.9% vs the previous count, 3.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Since Nov 19, 2025, GILD is up 30.0% and the index fund is up 4.1%: 26 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much GILD moves
A usual day
±1.1%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
2.7%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−4.0%Nov 5, 2026
Largest one-day rise
+5.8%Feb 11, 2026
Deepest fall of the year
−22.0%From the close of Feb 11, 2026 to Jun 10, 2026.
Days of 5% or more
2Out of 252 sessions, in either direction.
Beta 0.4(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
A Gilead Sciences officer told the SEC about a plan to sell $4.78M of Gilead Sciences shares around Nov 16, 2026. The shares were not acquired as compensation.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$8.3B
+6.8% vs the same quarter a year earlier
Free cash flow, last 12 months
$13.8B
This quarter $4.8B, a year earlier $3.96B
Net debt
$19.8B
Debt $26.2B, cash $6.44B, at Sep 30, 2026
Net income, last 12 months
−$3.86B
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 29, 2026.
Insiders of Gilead Sciences reported 8 open-market purchases and 2,865 sales since 2006; purchases in 6 different years, most recently 2015.
Year
Bought
Sold
2026
—
$104M80×80 trades
2025
—
$62.8M53×53 trades
2024
—
$50.1M24×24 trades
2023
—
$2.55M6×6 trades
2022
—
$3.15M6×6 trades
2021
—
$4.45M6×6 trades
2020
—
$9.88M23×23 trades
2019
—
$8.42M22×22 trades
2018
—
$70.3M53×53 trades
2017
—
$108M43×43 trades
2016
—
$182M56×56 trades
2015
$999K1×1 trade
$429M180×180 trades
2014
—
$375M180×180 trades
2013
$431K1×1 trade
$395M93×93 trades
2012
$440K1×1 trade
$202M90×90 trades
2011
—
$52.9M40×40 trades
2010
$494K2×2 trades
$44.9M32×32 trades
2009
$121K1×1 trade
$156M75×75 trades
2008
—
$133M624×624 trades
2007
$428K2×2 trades
$132M638×638 trades
2006
—
$117M541×541 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Last 30 days
Written by software from the filings listed below · Nov 13, 2026
Insiders.Gilead Sciences on OQRO In the 30 days to Nov 13, 2026, insiders filed 0 open-market purchases and 11 open-market sales (about $26.5M, in 5 filings, by 4 people). The largest sale was by Daniel Patrick O'day, Chairman & CEO, about $18M, filed Nov 6, 2026.
3 more points, with the facts they come from, are in OQRO Pro.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Late-stage clinical trials
27 active phase 3 trials and 31 active phase 2 trials led by this company, mostly in hiv-1-infection, pre-exposure prophylaxis of hiv infection, hiv-1 infection. The ones with the nearest registered primary completion date still ahead:
21 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Gilead Sciences filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 88 open-market sales (about $109M, in 46 filings, by 7 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 54 open-market sales (about $97.7M, in 33 filings). (Gilead Sciences on OQRO)
Congress. Members of Congress filed 4 disclosures on Gilead Sciences in the 12 months to Nov 19, 2026: 4 purchases and 0 sales, by 3 members. In the 12 months before that: 13 disclosures. The largest range: Sen. Alan Armstrong, $1,001 to $15,000, filed Jul 21, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 108 new or larger positions and 114 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter. FMR LLC now owns 5.3% of GILD as a passive investor (filed Feb 5, 2026).
Contracts, lobbying and filings. 38 lobbying reports naming the company were posted in the 12 months, reporting about $9.2M. The Federal Register published a notice, "Notice Pursuant to the National Cooperative Research and Production Act of 1993-R Consortium, Inc.", on Nov 10, 2026, naming the company.
Company reports, price and press. Gilead Sciences filed a Form 8-K on Oct 29, 2026 (Item 2.02) that OQRO classes as: reported its results. Gilead Sciences filed a Form 8-K on Aug 4, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 2,269 funds reported a stake in Gilead Sciences in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (10.9% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (7.3% of the value reported), FMR LLC (6.0% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Gilead Sciences filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 88 open-market sales (about $109M, in 46 filings, by 7 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 54 open-market sales (about $97.7M, in 33 filings).
The largest sale: Daniel Patrick O'day, Chairman & CEO, about $18M, filed Nov 6, 2026.
Congress
Members of Congress filed 4 disclosures on Gilead Sciences in the 12 months to Nov 19, 2026: 4 purchases and 0 sales, by 3 members. In the 12 months before that: 13 disclosures.
The largest range: Sen. Alan Armstrong, $1,001 to $15,000, filed Jul 21, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 108 new or larger positions and 114 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
FMR LLC now owns 5.3% of GILD as a passive investor (filed Feb 5, 2026).
Contracts, lobbying and filings
38 lobbying reports naming the company were posted in the 12 months, reporting about $9.2M.
The Federal Register published a notice, "Notice Pursuant to the National Cooperative Research and Production Act of 1993-R Consortium, Inc.", on Nov 10, 2026, naming the company.
The Federal Register published a notice, "Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Fo", on May 22, 2026, naming the company.
FDA records list 7 drug approvals for Gilead Sciences between Nov 19, 2025 and Nov 19, 2026; the latest, on Aug 27, 2026: drug approval for Bixlenvo Sunlenca Starter Pack (Copackaged) (New drug application approved. Active ingredient: Bictegravir Sodium, Lenacapavir Sodium, Lenacapavir Sodium).
ClinicalTrials.gov shows 10 studys sponsored by the company updated in the period; the latest, "Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infecti..." (Phase 2, status active not recruiting), was updated on Nov 12, 2026, with primary completion listed for 2026-10-27.
State WARN notices show 3 layoff notices filed by the company in the period, for 193 employees in CA; the latest was filed Apr 30, 2026 with an effective date of Jun 30, 2026.
FINRA short interest for GILD on the settlement date of Oct 30, 2026 was 21,271,970 shares (+4.94% on the previous report), about 3.18 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 30,538 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $28.4M for its principal executive officer, and an average of $9.25M for the other named executive officers.
Company reports, price and press
Gilead Sciences filed a Form 8-K on Oct 29, 2026 (Item 2.02) that OQRO classes as: reported its results.
Gilead Sciences filed a Form 8-K on Aug 4, 2026 (Item 2.02) that OQRO classes as: reported its results.
Gilead Sciences filed a Form 8-K on Nov 19, 2025 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On November 19 , 2025, Gilead Sciences, Inc., a Delaware corporation (the 'Company'), announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of D..."
Press coverage listed by Finnhub: "Where Could Gilead's Next Growth Come From?" (Yahoo, Nov 19, 2026).
Press coverage listed by Finnhub: "Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs" (Yahoo, Nov 17, 2026).
Press coverage listed by Finnhub: "Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting" (Yahoo, Nov 17, 2026).
GILD closed at $168.98 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $153.07 to $168.98, a change of +10.4%.
Who holds it
2,269 funds reported a stake in Gilead Sciences in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (10.9% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (7.3% of the value reported), FMR LLC (6.0% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
83 certified in FY2026 Q3, vs 51 a year earlier. 83 positions in total, median offered wage $159K a year.
Manager, Statistical Programming · 5Assoc Director, IT Engineering · 3Assoc Director, IT Architecture · 2Associate Scientist, Biology · 2Associate Scientist, Process Development · 2
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
FDA, last 12 months
7 approvals or clearances and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Risk factors in the annual report
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 28, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
Our U.S. manufacturing and R&D investments may not achieve their intended benefits and could adversely affect our business, results of operations and cash flows.
No longer listed (1 heading from the year before)
The failure to successfully implement or upgrade enterprise resource planning and other information systems could adversely impact our business and results of operations.
Legal proceedings (Item 3)
For a description of our significant pending legal proceedings, see Note 12. Commitments and Contingencies - Legal Proceedings of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Oct 30, 2026. Quarterly reports are not audited. Read the filing
By region
U.S.$6.36B77%
+20% on the same quarter a year earlier ($5.28B)
Europe$1.06B13%
−32% on the same quarter a year earlier ($1.55B)
Rest of World$872M11%
−6.5% on the same quarter a year earlier ($933M)
Total revenue$8.3B+6.8%
The full fiscal year ended Dec 31, 2025
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 24, 2026. Read the filing
By region
U.S.$20.9B71%
+1.4% on the year before ($20.6B)
Europe$5.06B17%
+9.3% on the year before ($4.63B)
Rest of World$3.5B12%
−0.7% on the year before ($3.53B)
Total revenue$29.4B+2.4%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “Management Overview”, in the company's words
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. Our strategic ambitions are to (i) bring 10+ transformative therapies to patients by 2030 (tracking since 2020); (ii) be a biotech employer and partner of choice; and (iii) deliver shareholder value in a sustainable and responsible manner.
What the section covers (36 headings)
Management Overview
Year in Review
Virology
Oncology
Inflammation
Corporate
Outlook
Results of Operations
Revenues
Liver Disease
Veklury
Cell Therapy
Trodelvy
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026 and Form 10-Q filed Oct 30, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Gross-to-Net Deductions
And 22 more headings in the filing.
When insiders usually buy
Last results
Oct 29, 2026
Within the 30 days after it, until Nov 28, 2026
Next results, expected
Feb 8, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Gilead Sciences's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Gilead Sciences's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Short sale volume: 46.0% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 42.1%. FINRA daily files, to Nov 20, 2026.
Fails to deliver: 81K shares (about $12M) were not delivered on time for settlement on Oct 9, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 41.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (23.1% on ATS, 17.9% with other brokers), close to its 26-week average of 41.1%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: INTELLIGENT CROSS LLC (12.9%), UBS ATS (12.5%), SIGMA X2 (10.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.